Celcuity CEO to Present at Two Key Investor Conferences

Event summary

Celcuity CEO Brian Sullivan to present at Wells Fargo Healthcare Conference on September 8, 2026.
Sullivan also scheduled for Citi Biopharma Back to School Summit on September 9, 2026.
Live webcasts available via company's investor relations page.
Celcuity's REVTORPYK™ (gedatolisib) recently gained FDA approval for specific breast cancer indications.
Ongoing Phase 3 trials (VIKTORIA-2) and Phase 1/2 trials (CELC-G-201) for additional cancer indications.

The big picture

Celcuity's participation in high-profile investor conferences comes at a critical juncture following FDA approval of its lead product, REVTORPYK. The company is positioning itself to expand its clinical pipeline while capitalizing on recent regulatory success. The biotech sector continues to face challenges in balancing innovation with commercialization timelines, making Celcuity's strategic updates particularly relevant for investors tracking oncology-focused therapeutics.

What we're watching

Clinical Trial Progress: How the ongoing VIKTORIA-2 and CELC-G-201 trials will impact REVTORPYK's market potential.
Regulatory Strategy: Whether Celcuity can leverage FDA approval to expand into additional cancer indications.
Investor Sentiment: The pace at which investor interest translates into market valuation following conference presentations.